The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...

This expected growth is supported by an increase in supply, heightened promotional activities, and broader label coverage for Zepbound, all contributing to a healthy demand trajectory ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

After that, your doctor may increase your dosage to 5 mg once per week. There is no best time of day to give Zepbound. It can be given at any point in time during the day, with or without food.

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues. ‘#Obesity Market Shift? #Eli_Lilly's #Zepbound could ...

Zepbound is an injectable prescription medication ... Furthermore, up to 50% of participants no longer exhibited symptoms of OSA. The medication also promotes weight loss, with patients losing ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity. Nearly half of clinical trial patients saw such ...